Clinical utility of treprostinil in the treatment of pulmonary arterial hypertension: an evidence-based review
Mitchell S Buckley,1 Andrew J Berry,1 Nadine H Kazem,2 Shardool A Patel,3 Paul A Librodo41Department of Pharmacy, Banner Good Samaritan Medical Center, Phoenix, AZ, USA; 2Department of Pharmacy, St Joseph’s Hospital and Medical Center, Phoenix, AZ, USA; 3Department of Pharmacy, Banner Estrella Medical Center, Phoenix, AZ, USA; 4Department of Pharmacy, San Francisco VA Medical Center, San Francisco, CA, USAAbstract: Pulmonary arterial hypertension (PAH) remains a progressive disease without a cure, despite the development of several treatment options over the past several decades. Its management strategy consists of t...
Source: Core Evidence - June 19, 2014 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research
corrigendum
Vaishampayan UN (Source: Core Evidence)
Source: Core Evidence - May 15, 2014 Category: Drugs & Pharmacology Source Type: research
Development of cabozantinib for the treatment of prostate cancer [Corrigendum]
(Source: Core Evidence)
Source: Core Evidence - May 15, 2014 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research
Cabozantinib in prostate cancer
Vaishampayan UN (Source: Core Evidence)
Source: Core Evidence - April 22, 2014 Category: Drugs & Pharmacology Source Type: research
Development of cabozantinib for the treatment of prostate cancer
Ulka N VaishampayanDepartment of Oncology, Wayne State University/Karmanos Cancer Institute, Detroit, MI, USAAbstract: Cabozantinib (XL184) is a multitargeted receptor tyrosine kinase with predominantly MET and vascular endothelial growth factor inhibition properties. It is currently approved by the US Food and Drug Administration for the treatment of progressive metastatic medullary thyroid cancer. The agent has a convenient once-daily oral dosing schedule and has demonstrated encouraging activity in metastatic castrate-resistant prostate cancer (CRPC). A Phase I/II trial demonstrated responses in soft tissue, visceral di...
Source: Core Evidence - April 22, 2014 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research
Ocriplasmin for symptomatic vitreomacular adhesion
Song SJ, Smiddy WE (Source: Core Evidence)
Source: Core Evidence - March 20, 2014 Category: Drugs & Pharmacology Source Type: research
Ocriplasmin for symptomatic vitreomacular adhesion: an evidence-based review of its potential
Su Jeong Song,1,2 William E Smiddy1 1Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA; 2Department of Ophthalmology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea Abstract: Vitreomacular traction is a multicategory entity that may cause substantial visual loss due to the formation of a macular hole or traction-induced tissue distortion. The advent of optical coherent tomography (OCT) has demonstrated the anatomic features of persistent vitreomacular attachment (VMA) more definitively, including in many asympto...
Source: Core Evidence - March 20, 2014 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research
Eptifibatide: The evidence for its role in the management of acute coronary syndromes
Shah I, Khan SO, Malhotra S, Fischell T (Source: Core Evidence)
Source: Core Evidence - March 14, 2014 Category: Drugs & Pharmacology Source Type: research
Eptifibatide: The evidence for its role in the management of acute coronary syndromes [Corrigendum]
(Source: Core Evidence)
Source: Core Evidence - March 13, 2014 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research
Mavrilimumab and rheumatoid arthritis
Di Franco M, Gerardi MC, Lucchino B, Conti F (Source: Core Evidence)
Source: Core Evidence - March 11, 2014 Category: Drugs & Pharmacology Source Type: research
